{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:28Z","timestamp":1794047428346,"version":"4.8.0"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between \u2018lowgrade\u2019 (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics and outcomes are poorly understood due to lack of adequate representation in prospective trials and large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, and two comparator groups; G3AFL (n=302) and DLBCL (n=548). Composite histology with DLBCL or low-grade FL occurred in approximately half of the G3BFL cases. With a median of 5 years follow-up, the overall survival and progression-free survival of G3BFL patients was better than that of DLBCL patients (P&lt;0.001 and P&lt;0.001, respectively); however, G3BFL patients were younger (P&lt;0.001) with better performance status (P&lt;0.001), less extranodal disease (P&lt;0.001) and more frequently had normal lactate dehydrogenase (P&lt;0.001) at baseline. The overall and progression-free survival of patients with G3BFL and G3AFL were similar (P=0.83 and P=0.80, respectively). After frontline immunochemotherapy, 24% of G3BFL relapsed; relapse rates were 63% in the DLBCL cohort and 19% in the low-grade FL cohort. Eight percent of relapses occurred beyond 5 years. In this G3BFL cohort, the revised International Prognostic Index successfully delineated risk groups, but the Follicular Lymphoma International Prognostic Index did not. We conclude that patients with immunochemotherapy-treated G3BFL have similar survival outcomes to those with G3AFL, yet a favorable baseline profile and distinctly superior prognosis compared to patients with DLBCL.<\/jats:p>","DOI":"10.3324\/haematol.2022.281375","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T03:28:46Z","timestamp":1677122926000},"page":"2444-2453","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance"],"prefix":"10.3324","volume":"108","author":[{"given":"Allison","family":"Barraclough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Wight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Hapgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Wong","family":"Doo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Wenlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briony","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Bishton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Ratnasingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chathuri","family":"Abeyakoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Hnin","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Peng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Yun","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tukten","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Narayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"51589","doi-asserted-by":"crossref","unstructured":"The Non-Hodgkins Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997; 89(11):3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"51590","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"51591","doi-asserted-by":"crossref","unstructured":"Chau I, Jones R, Cunningham D. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. Br J Cancer. 2003; 89(1):36-42.","DOI":"10.1038\/sj.bjc.6601006"},{"key":"51592","doi-asserted-by":"crossref","unstructured":"Wahlin BE, Yri OE, Kimby E. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012; 156(2):225-233.","DOI":"10.1111\/j.1365-2141.2011.08942.x"},{"key":"51593","doi-asserted-by":"crossref","unstructured":"Martin A, Weisenburger D, Chan W. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995; 85(12):3671-3678.","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671"},{"key":"51594","doi-asserted-by":"crossref","unstructured":"Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2011; 22(5):1164-1169.","DOI":"10.1093\/annonc\/mdq574"},{"key":"51595","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008."},{"key":"51596","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"51597","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36(7):1720-1748.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"51598","doi-asserted-by":"crossref","unstructured":"Martin AR, Weisenburger DD, Chan WC. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995; 85(12):3671-3678.","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671"},{"key":"51599","doi-asserted-by":"crossref","unstructured":"Rodriguez J, McLaughlin P, Hagemeister FB. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood. 1999; 93(7):2202-2207.","DOI":"10.1182\/blood.V93.7.2202"},{"key":"51600","doi-asserted-by":"crossref","unstructured":"Strati P, Fowler N, Pina-Oviedo S. Long-term remissions of patients with follicular lymphoma grade 3 treated with R-CHOP. Clin Lymphoma Myeloma Leuk. 2018; 18(1):e103-e108.","DOI":"10.1016\/j.clml.2017.11.001"},{"key":"51601","doi-asserted-by":"crossref","unstructured":"Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ. Follicular large-cell lymphoma: intermediate or low grade?. J Clin Oncol. 1994; 12(7):1349-1357.","DOI":"10.1200\/JCO.1994.12.7.1349"},{"key":"51602","doi-asserted-by":"crossref","unstructured":"Wendum D, Sebban C, Gaulard P. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(4):1654-1663.","DOI":"10.1200\/JCO.1997.15.4.1654"},{"key":"51603","doi-asserted-by":"crossref","unstructured":"Mustafa Ali M, Rybicki L, Nomani L. Grade 3 follicular lymphoma: outcomes in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017; 17(12):797-803.","DOI":"10.1016\/j.clml.2017.07.002"},{"key":"51604","doi-asserted-by":"crossref","unstructured":"Barraclough A, Bishton M, Cheah CY, Villa D, Hawkes EA. The diagnostic and therapeutic challenges of grade 3B follicular lymphoma. Br J Haematol. 2021; 195(1):15-24.","DOI":"10.1111\/bjh.17404"},{"key":"51605","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(Suppl 5):v83-v90.","DOI":"10.1093\/annonc\/mdw400"},{"key":"51606","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 2.2023 Follicular Lymphoma (grade 1-2).Publisher Full Text|"},{"key":"51607","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"51608","doi-asserted-by":"crossref","unstructured":"Flinn IW, van der Jagt R, Kahl BS. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014; 123(19):2944-2952.","DOI":"10.1182\/blood-2013-11-531327"},{"key":"51609","doi-asserted-by":"crossref","unstructured":"Marcus R, Davies A, Ando K. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017; 377(14):1331-1344.","DOI":"10.1056\/NEJMoa1614598"},{"key":"51610","doi-asserted-by":"crossref","unstructured":"Barraclough A, Chong G, Gilbertson M. Immune priming with single-agent nivolumab followed by combined nivolumab &amp; rituximab is safe and efficacious for first-line treatment of follicular lymphoma; interim analysis of the '1st FLOR' Study. Blood. 2019; 134(Suppl_1):1523.","DOI":"10.1182\/blood-2019-123908"},{"key":"51611","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"51612","doi-asserted-by":"crossref","unstructured":"Casulo C, Byrtek M, Dawson KL. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-2522.","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"51613","doi-asserted-by":"crossref","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P. Follicular Lymphoma International Prognostic Index. Blood. 2004; 104(5):1258-1265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"51614","doi-asserted-by":"crossref","unstructured":"Sehn LH, Berry B, Chhanabhai M. The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5):1857-1861.","DOI":"10.1182\/blood-2006-08-038257"},{"key":"51615","doi-asserted-by":"crossref","unstructured":"Yuan J, Greiner TC, Fu K. Rituximab improves the outcome of patients with grade 3 follicular lymphoma receiving anthracycline-based therapy. Clin Lymphoma Myeloma Leuk. 2017; 17(8):488-497.e2.","DOI":"10.1016\/j.clml.2017.06.006"},{"key":"51616","doi-asserted-by":"crossref","unstructured":"Ott G, Katzenberger T, Lohr A. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002; 99(10):3806-3812.","DOI":"10.1182\/blood.V99.10.3806"},{"key":"51617","doi-asserted-by":"crossref","unstructured":"Koch K, Hoster E, Ziepert M. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016; 27(7):1323-1329.","DOI":"10.1093\/annonc\/mdw185"},{"key":"51618","doi-asserted-by":"crossref","unstructured":"Horn H, Kohler C, Witzig R. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica. 2018; 103(7):1182-1190.","DOI":"10.3324\/haematol.2017.181024"},{"key":"51619","doi-asserted-by":"crossref","unstructured":"Piccaluga PP, Califano A, Klein U. Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica. 2008; 93(7):1033-1038.","DOI":"10.3324\/haematol.12754"},{"key":"51620","doi-asserted-by":"crossref","unstructured":"Reddy A, Zhang J, Davis NS. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017; 171(2):481-494.","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"51621","doi-asserted-by":"crossref","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018; 36(16):1603-1610.","DOI":"10.1200\/JCO.2017.76.5198"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281375\/75395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281375\/75959","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10991\/75395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:34Z","timestamp":1794045814000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281375","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,23]]}}}